Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

May 04, 2015 12:07 PM ET


Company Overview of Marinus Pharmaceuticals, Inc.

Company Overview

Marinus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing neuropsychiatric therapeutics. It is developing ganaxolone, a small molecule, which is in Phase III clinical trials to treat patients with refractory focal onset seizures; and is in Phase II clinical trials for the treatment of orphan disease, as well as is in Phase II crossover clinical study to treat behaviors in Fragile X Syndrome, an orphan indication. The company is also developing an IV formulation for use in the hospital setting to control acute seizures. It has a collaboration agreement with NovaMedica, LLC; and license agreement with Purdue Neuroscience Company. Marin...

Three Radnor Corporate Center

Suite 304

100 Matsonford Road

Radnor, PA 19087

United States

Founded in 2003

9 Employees



Key Executives for Marinus Pharmaceuticals, Inc.

Executive Chairman, Chief Executive Officer and President
Age: 57
Total Annual Compensation: $455.0K
Chief Financial Officer, Vice President, Treasurer and Secretary
Age: 43
Total Annual Compensation: $405.0K
Chief Clinical Development & Regulatory Officer
Age: 50
Total Annual Compensation: $358.9K
Chief Medical Officer
Age: 49
Compensation as of Fiscal Year 2014.

Marinus Pharmaceuticals, Inc. Key Developments

Marinus Pharmaceuticals, Inc., Annual General Meeting, Apr 21, 2015

Marinus Pharmaceuticals, Inc., Annual General Meeting, Apr 21, 2015., at 09:30 US Eastern Standard Time. Location: The NASDAQ MarketSite, 4 Times Square, 2nd Floor. Agenda: To consider the election of two Class I director nominees; to ratify the selection of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2015; and to transact such other business as may properly be brought before the Annual Meeting or any adjournment or postponement thereof.

Marinus Pharmaceuticals, Inc. Reports Unaudited Earnings Results for the Year Ended December 31, 2014

Marinus Pharmaceuticals, Inc. reported unaudited earnings results for the year ended December 31, 2014. The company reported net losses of $10.8 million and $5.3 million for the years ended December 31, 2014 and 2013, respectively. Cash used in operating activities was $8.6 million compared to $6.6 million for the same period a year ago. Loss from operations was $11.9 million against $5.4 million a year ago. Net loss applicable to common stockholders $13.4 million against $9.1 million a year ago. Net loss per share of common stock - basic and diluted was $2.17 against $19.60 a year ago.

Marinus Pharmaceuticals, Inc. Presents at BioCentury 22nd Annual Future Leaders in the Biotech Industry Conference, Mar-20-2015 10:00 AM

Marinus Pharmaceuticals, Inc. Presents at BioCentury 22nd Annual Future Leaders in the Biotech Industry Conference, Mar-20-2015 10:00 AM. Venue: Millennium Broadway Hotel & Conference Center, New York, New York, United States. Speakers: Christopher Michael Cashman, Executive Chairman, Chief Executive Officer and President.

Similar Private Companies By Industry

Company Name Region
Seaside Therapeutics, LLC United States
Arcturus Pharmaceutical Corporation United States
A-Life, Inc. United States
Hisamitsu America Inc. United States
ExoVita Biosciences, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Marinus Pharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at